Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 7/20 | 0.39 |
| ▸ | CYP46A1 | Q9Y6A2 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.35 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.34 |
| ▸ | MAOA | P21397 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
| ▸ | GRK2 | P25098 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | FDPS | P14324 | 1/20 | 0.33 |
| ▸ | CDC25B | P30305 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28763025 | 0.88 | L3MBTL1 (0.43) | L3MBTL1KDM4EMEN1MAPTKMT2A | |
| SCHEMBL2883707 | 0.77 | MAPT (0.50) | L3MBTL1KDM4EMEN1MAPTKMT2A | |
| SCHEMBL4956642 | 0.75 | ACHE (0.43) | L3MBTL1KDM4EMEN1MAPTKMT2A | |
| SCHEMBL6793951 | 0.75 | CYP19A1 (0.51) | CYP19A1MAOB | |
| SCHEMBL5257437 | 0.75 | CYP26A1 (0.56) | CYP19A1MAOAMAOB | |
| Bromide SCHEMBL8113723 | 0.74 | CYP19A1 (0.49) | CYP19A1 | |
| SCHEMBL27742809 | 0.73 | CYP19A1 (0.43) | L3MBTL1KDM4EMEN1MAPTKMT2A | |
| SCHEMBL3603056 | 0.73 | CYP19A1 (0.43) | MAPTCYP19A1MAOAMAOBCDC25B | |
| SCHEMBL14161098 | 0.73 | CYP19A1 (0.43) | L3MBTL1KDM4EMEN1MAPTKMT2A | |
| Bromide SCHEMBL3598820 | 0.72 | CYP19A1 (0.42) | MAPTCYP19A1MAOAMAOBFDPS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080269209-A1 | Pyrazoloisoquinoline Derivatives | PALAU PHARMA, S.A. (ES) | 2008-10-30 | — | — | US | disclosed |
| EP-1960400-A1 | PYRAZOLOISOQUINOLINE DERIVATIVES | Palau Pharma, S.A. (ES) | 2008-08-27 | — | — | EP | disclosed |
| WO-2007060198-A1 | PYRAZOLOISOQUINOLINE DERIVATIVES | PALAU PHARMA, S. A. (ES) | 2007-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269209-A1 | Pyrazoloisoquinoline Derivatives | MAP4K2, MAPK1, MAPKAPK2 | L3MBTL1 3568/4885KDM4E 3422/4885MEN1 3868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.